{"organizations": [], "uuid": "ccfb24ec544bec9d3adaf9bd4199d9fdd438dc59", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180419.html", "section_title": "Archive News &amp; Video for Thursday, 19 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/shire-ma-takeda-pharma-bid/takeda-in-talks-with-shire-after-46-50-stg-shr-bid-rejected-idUSL8N1RW4GO", "country": "US", "domain_rank": 408, "title": "Takeda in talks with Shire after 46.50 stg/shr bid rejected", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.033, "site_type": "news", "published": "2018-04-19T20:23:00.000+03:00", "replies_count": 0, "uuid": "ccfb24ec544bec9d3adaf9bd4199d9fdd438dc59"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/shire-ma-takeda-pharma-bid/takeda-in-talks-with-shire-after-46-50-stg-shr-bid-rejected-idUSL8N1RW4GO", "ord_in_thread": 0, "title": "Takeda in talks with Shire after 46.50 stg/shr bid rejected", "locations": [], "entities": {"persons": [{"name": "takeda", "sentiment": "negative"}, {"name": "ben hirschler", "sentiment": "none"}, {"name": "susan fenton", "sentiment": "none"}], "locations": [{"name": "london", "sentiment": "none"}, {"name": "japan", "sentiment": "none"}], "organizations": [{"name": "shire", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "takeda pharmaceutical", "sentiment": "negative"}]}, "highlightText": "", "language": "english", "persons": [], "text": "LONDON, April 19 (Reuters) - Japanâ€™s Takeda Pharmaceutical said on Thursday it was in negotiations with Shire after making a bid worth 46.50 pounds per share that was rejected by the London-listed rare diseases drugmaker.\nReuters first reported that Takeda had made the cash-and-stock takeover offer, valuing Shire at around $61 billion. (Reporting by Ben Hirschler; Editing by Susan Fenton)\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-19T20:23:00.000+03:00", "crawled": "2018-04-20T11:48:35.000+03:00", "highlightTitle": ""}